Patterson Companies Reports Fiscal 2023 Second Quarter Operating Results

Rhea-AI Summary

Patterson Companies reported net sales of $1.63 billion for Q2 fiscal 2023, a 1.4% decline year-over-year. However, adjusted operating margins improved across both Dental and Animal Health segments. The company achieved a GAAP earnings of $0.55 per diluted share, up from $0.49 a year earlier, and adjusted earnings of $0.63, a 9% increase. Despite external challenges, Patterson reaffirmed its fiscal 2023 guidance, projecting GAAP earnings between $1.96 and $2.06 per share. The report indicates internal sales growth in equipment, though consumables faced declines.

Positive

• Improved adjusted earnings of $0.63 per diluted share, a 9% increase year-over-year.
• Reaffirmed fiscal 2023 GAAP earnings guidance of $1.96 to $2.06 per diluted share.

Negative

• Q2 net sales decreased 1.4% compared to the prior year.
• Internal sales of consumables declined 4.9% year-over-year.

• Achieved second quarter reported net sales of $1.6 billion.
• Drove adjusted operating margin expansion across both Dental and Animal Health segments.
• Delivered second quarter GAAP earnings of $0.55 per diluted share and adjusted earnings¹ of $0.63 per diluted share, an increase of 9 percent over prior year.
• Reaffirmed fiscal 2023 GAAP earnings guidance of $1.96 to $2.06 per diluted share and adjusted earnings¹ guidance of $2.25 to $2.35 per diluted share.

ST. PAUL, Minn.--(BUSINESS WIRE)-- Patterson Companies, Inc. (Nasdaq: PDCO) today reported consolidated net sales of $1.63 billion (see attached Sales Summary for further details) in its fiscal second quarter ended October 29, 2022, a decrease of 1.4 percent compared to the same period last year. Internal sales, which are adjusted for the effects of currency translation, increased 0.7 percent over the prior year period.

Reported net income attributable to Patterson Companies, Inc. for the second quarter of fiscal 2023 was $54.1 million, or $0.55 per diluted share, compared to $48.3 million, or $0.49 per diluted share, in the second quarter of fiscal 2022. Adjusted net income¹ attributable to Patterson Companies, Inc., which excludes deal amortization and integration and business restructuring expenses, totaled $61.2 million for the second quarter of fiscal 2023, or $0.63 per diluted share, compared to $57.1 million, or $0.58 per diluted share, in the second quarter of fiscal 2022. The year-over-year increase in reported and adjusted net income attributable to Patterson Companies, Inc. in the second quarter of fiscal 2023 is primarily due to operating margin expansion in both business segments.

“Our second quarter results reflect the strength of our strategy and talented team,” said Don Zurbay, President and CEO of Patterson Companies. “Despite ongoing challenges in the macroeconomic environment, Patterson delivered internal sales growth, operating margin expansion in both of our segments and improved adjusted earnings performance. We also continued to execute our balanced capital allocation strategy by investing in our business, returning cash to shareholders and announcing two strategic transactions that deepen our value proposition.

“Patterson is well-positioned to achieve our goals and drive long-term shareholder value through the continued execution of our proven strategy. We remain committed to delivering on our fiscal 2023 EPS guidance.”

Patterson Dental

Reported net sales in the Dental segment for the second quarter of fiscal 2023 were $628.9 million. Internal sales increased 1.6 percent compared to the fiscal 2022 second quarter. Internal sales of consumables declined 4.9 percent year-over-year primarily due to the continued moderation of infection control products compared to the pandemic-related performance in the year-ago period. Excluding infection control products, internal sales of consumables increased 1.0 percent year-over-year. Compared to the prior year period, internal sales of equipment increased 11.1 percent and internal sales of value-added services increased 7.8 percent.

Patterson Animal Health

Reported net sales in the Animal Health segment for the second quarter of fiscal 2023 were $1.0 billion. Internal sales growth of 0.7 percent year-over-year was driven by mid-single digit growth in companion animal and a low-single digit decline in production animal. Within the Animal Health segment, internal sales of consumables grew 0.6 percent, equipment and software decreased 1.6 percent and value-added services increased 19.5 percent compared to the prior year period.

Balance Sheet and Capital Allocation

During the first six months of fiscal 2023, Patterson Companies used $520.2 million of cash from operating activities and collected deferred purchase price receivables of $489.6 million, using $30.5 million in cash, compared to generating $46.6 million in the prior year period. Free cash flow¹ (see definition below and attached free cash flow table) during the first six months of fiscal 2023 declined by $88.4 million compared to the first six months of fiscal 2022 due to an increased level of working capital during the first six months of fiscal 2023.

In the second quarter of fiscal 2023, Patterson Companies declared a quarterly cash dividend of $0.26 per share and returned $25.3 million in cash dividends to shareholders. Through the first six months of fiscal 2023, Patterson Companies has returned $65.7 million to shareholders through cash dividends and share repurchases.

Year-to-Date Results

Consolidated reported net sales for the first six months of fiscal 2023 totaled $3.1 billion, a 3.5 percent year-over-year decrease. Sales in the first six months of fiscal 2022 reflected an extra week of sales results in the first quarter of fiscal 2022. Internal sales for the first six months of fiscal 2023, which are adjusted for the effects of currency translation and the extra week of selling results in the first quarter of fiscal 2022, increased 1.9 percent year-over-year. Through the first six months of fiscal 2023, Dental segment internal sales increased 0.5 percent, including a 3.8 percent decline in consumables and 6.5 percent growth in equipment and software. Through the first six months of fiscal 2023, Animal Health segment internal sales increased 3.1 percent, including 3.0 percent growth in consumables and 4.4 percent growth in equipment and software.

Reported net income attributable to Patterson Companies, Inc. was $78.7 million, or $0.81 per diluted share, compared to $82.3 million, or $0.84 per diluted share in last year's period. Adjusted net income¹ attributable to Patterson Companies, Inc., which excludes deal amortization, integration and business restructuring expenses, legal reserves, inventory donation charges and gains on investments totaled $92.9 million, or $0.95 per diluted share, compared to $99.2 million, or $1.01 per diluted share, in the year-ago period.

Fiscal 2023 Guidance

Patterson Companies today reaffirmed its fiscal 2023 earnings guidance, which is provided on both a GAAP and non-GAAP adjusted¹ basis:

• GAAP earnings are expected to be in the range of $1.96 to $2.06 per diluted share.
• Non-GAAP adjusted earnings¹ are expected to be in the range of $2.25 to $2.35 per diluted share.
• Our non-GAAP adjusted earnings¹ guidance excludes the after-tax impact of:
  • Deal amortization expenses of approximately $28.5 million ($0.29 per diluted share).

Our guidance reflects the strength of our business and competitive positioning, as well as our expectations for the North American and international end markets in which we operate, which we expect to be affected by the ongoing challenges of inflationary trends and higher interest rates as well as a potential slow-down in the broader economy. Beyond macroeconomic and geopolitical uncertainty, our guidance further assumes that there are no material adverse developments associated with the pandemic.

¹Non-GAAP Financial Measures

The Reconciliation of GAAP to non-GAAP Measures table appearing behind the accompanying financial information is provided to adjust reported GAAP measures, namely operating income, other income (expense), net income before taxes, income tax expense, net income, net income attributable to Patterson Companies, Inc. and diluted earnings per share attributable to Patterson Companies, Inc., for the impact of deal amortization, integration and business restructuring expenses, legal reserves, inventory donation charges and gains on investments along with the related tax effects of these items.

The term “free cash flow” used in this release is defined as net cash used in operating activities less capital expenditures plus the collection of deferred purchase price receivables.

In addition, the term “internal sales” used in this release represents net sales adjusted to exclude the impact of foreign currency and the extra week of selling results in the first quarter of fiscal 2022. Foreign currency impact represents the difference in results that is attributable to fluctuations in currency exchange rates the company uses to convert results for all foreign entities where the functional currency is not the U.S. dollar. The company calculates the impact as the difference between the current period results translated using the current period currency exchange rates and using the comparable prior period's currency exchange rates. The company believes the disclosure of net sales changes in constant currency provides useful supplementary information to investors in light of fluctuations in currency rates.

Management believes that these non-GAAP measures may provide a helpful representation of the company's second quarter performance and enable comparison of financial results between periods where certain items may vary independent of business performance. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures.

Second Quarter Conference Call and Replay

Patterson Companies’ fiscal 2023 second quarter conference call will start at 8:30 a.m. Eastern today. Investors can listen to a live webcast of the conference call at www.pattersoncompanies.com. The conference call will be archived on the Patterson Companies website. A replay of the fiscal 2023 second quarter conference call can be heard for one week at 1-800-770-2030 and by providing the Conference ID 71954 when prompted.

About Patterson Companies Inc.

Patterson Companies Inc. (Nasdaq: PDCO) connects dental and animal health customers in North America and the U.K. to the latest products, technologies, services and innovative business solutions that enable operational and professional success. Our comprehensive portfolio, distribution network and supply chain is equaled only by our dedicated, knowledgeable people who deliver unrivalled expertise and unmatched customer service and support.

Learn more: pattersoncompanies.com

This press release contains, and our officers and representatives may from time to time make, certain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding future financial performance, and the objectives and expectations of management. Forward-looking statements often include words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “seeks” or words of similar meaning, or future or conditional verbs, such as “will,” “should,” “could” or “may.”

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.

Any number of factors could affect our actual results and cause such results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the following: the COVID-19 pandemic and measures taken in response thereto; uncertain macro-economic conditions, including inflationary pressures; our dependence on relationships with sales representatives and service technicians to retain customers and develop business; potential disruption of distribution capabilities, including service issues with third-party shippers; our dependence on suppliers to manufacture and supply substantially all of the products we sell; the risk of the products we sell becoming obsolete or containing undetected errors; adverse changes in supplier rebates or other purchasing incentives; the risk that private label sales could adversely affect our relationships with suppliers; our dependence on positive perceptions of Patterson’s reputation; risks inherent in acquiring and disposing of assets or other businesses and the risks inherent in integrating acquired businesses; our ability to comply with restrictive covenants in our credit agreement; turnover or loss of key personnel or highly skilled employees; the risk that our governing documents and Minnesota law may discourage takeovers and business combinations; risks related to climate change; the effects of the highly competitive and consolidating dental and animal health supply markets in which we compete; exposure to the risks of the animal production business, including changing consumer demand, the cyclical livestock market, and other factors outside our control, and the risks of the companion animal business, including the possibility of disease adversely affecting the pet population; risks from the formation or expansion of GPOs, provider networks and buying groups that may shift purchasing decisions and place us at a competitive disadvantage; increases in over-the-counter sales and e-commerce options for companion animal products or sales of companion animal products from non-veterinarian sources; change and uncertainty in the health care industry; failure to comply with existing or future U.S. or foreign laws and regulations including those governing the distribution of pharmaceuticals and controlled substances; failure to comply with health care fraud or other laws and regulations; litigation risks, including the diversion of management’s attention, the cost of defending against such actions, the possibility of damage awards or settlements, fines or penalties, or equitable remedies (including but not limited to the revocation of or non-renewal of licenses) and inherent uncertainty; failure to comply with evolving data privacy laws and regulations; tax legislation; the risks inherent in international operations, including currency fluctuations; and risks associated with information systems, software products and cyber-security attacks.

The order in which these factors appear should not be construed to indicate their relative importance or priority. We caution that these factors may not be exhaustive, accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results.

You should carefully consider these and other relevant factors, including those risk factors in Part I, Item 1A, (“Risk Factors”) in our most recent Form 10-K and information which may be contained in our other filings with the U.S. Securities and Exchange Commission, or SEC, when reviewing any forward-looking statement.

Investors should understand it is impossible to predict or identify all such factors or risks. As such, you should not consider the foregoing list, or the risks identified in our SEC filings, to be a complete discussion of all potential risks or uncertainties.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We do not undertake any obligation to release publicly any revisions to any forward-looking statements whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

PATTERSON COMPANIES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited)
		Three Months Ended								Six Months Ended
		October 29, 2022				October 30, 2021				October 29, 2022				October 30, 2021
Net sales		$	1,626,204			$	1,649,161			$	3,149,469			$	3,264,037
Gross profit			328,089				326,435				640,222				604,237
Operating expenses			267,994				263,575				545,283				580,906
Operating income			60,095				62,860				94,939				23,331
Other income (expense):
Gains on investments			—				—				—				87,827
Other income, net			18,203				6,804				19,983				8,227
Interest expense			(7,544	)			(5,521	)			(13,107	)			(10,716	)
Income before taxes			70,754				64,143				101,815				108,669
Income tax expense			17,105				16,205				23,906				26,929
Net income			53,649				47,938				77,909				81,740
Net loss attributable to noncontrolling interests			(424	)			(392	)			(754	)			(586	)
Net income attributable to Patterson Companies, Inc.		$	54,073			$	48,330			$	78,663			$	82,326
Earnings per share attributable to Patterson Companies, Inc.:
Basic		$	0.56			$	0.50			$	0.81			$	0.85
Diluted		$	0.55			$	0.49			$	0.81			$	0.84
Weighted average shares:
Basic			96,913				97,321				96,771				97,089
Diluted			97,552				98,363				97,708				98,363
Dividends declared per common share		$	0.26			$	0.26			$	0.52			$	0.52

PATTERSON COMPANIES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited)
		October 29, 2022			April 30, 2022
ASSETS
Current assets:
Cash and cash equivalents		$	140,280		$	142,014
Receivables, net			454,649			447,162
Inventory			877,435			785,604
Prepaid expenses and other current assets			353,170			304,242
Total current assets			1,825,534			1,679,022
Property and equipment, net			208,120			213,140
Operating lease right-of-use assets, net			73,874			70,722
Goodwill and identifiable intangibles, net			372,845			393,244
Investments			157,777			139,182
Long-term receivables, net and other			242,318			246,320
Total assets		$	2,880,468		$	2,741,630
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable		$	714,713		$	681,321
Other accrued liabilities			223,779			276,000
Operating lease liabilities			28,331			29,348
Current maturities of long-term debt			3,000			—
Borrowings on revolving credit			174,000			29,000
Total current liabilities			1,143,823			1,015,669
Long-term debt			485,522			488,554
Non-current operating lease liabilities			47,986			43,332
Other non-current liabilities			161,029			151,440
Total liabilities			1,838,360			1,698,995
Stockholders' equity			1,042,108			1,042,635
Total liabilities and stockholders' equity		$	2,880,468		$	2,741,630

PATTERSON COMPANIES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)
		Six Months Ended
		October 29, 2022				October 30, 2021
Operating activities:
Net income		$	77,909			$	81,740
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization			41,090				40,980
Gains on investments			—				(87,827	)
Non-cash employee compensation			8,393				13,497
Non-cash losses (gains) and other, net			5,085				3,974
Change in assets and liabilities:
Receivables			(508,811	)			(583,939	)
Inventory			(100,596	)			(90,728	)
Accounts payable			41,557				165,250
Accrued liabilities			(47,519	)			(56,029	)
Other changes from operating activities, net			(37,269	)			(25,932	)
Net cash used in operating activities			(520,161	)			(539,014	)
Investing activities:
Additions to property and equipment			(26,779	)			(15,503	)
Collection of deferred purchase price receivables			489,639				585,647
Payments related to acquisitions, net of cash acquired			—				(19,793	)
Payments related to investments			(15,000	)			—
Sale of investments			—				57,245
Net cash provided by investing activities			447,860				607,596
Financing activities:
Dividends paid			(50,732	)			(50,407	)
Repurchases of common stock			(15,000	)			—
Draw (payment) on revolving credit			145,000				(10,000	)
Other financing activities			(1,766	)			1,959
Net cash provided by (used in) financing activities			77,502				(58,448	)
Effect of exchange rate changes on cash			(6,935	)			774
Net change in cash and cash equivalents			(1,734	)			10,908
Cash and cash equivalents at beginning of period			142,014				143,244
Cash and cash equivalents at end of period		$	140,280			$	154,152

PATTERSON COMPANIES, INC. SALES SUMMARY (Dollars in thousands) (Unaudited)
		October 29, 2022				October 30, 2021				Total Sales Growth			Foreign Exchange Impact			53rd Week			Internal Sales Growth
Three Months Ended
Consolidated net sales
Consumable		$	1,301,256			$	1,344,812			(3.2	)%		(2.4	)%		—	%		(0.8	)%
Equipment and software			243,896				223,813			9.0			(0.5	)		—			9.5
Value-added services and other			81,052				80,536			0.6			(2.1	)		—			2.7
Total		$	1,626,204			$	1,649,161			(1.4	)%		(2.1	)%		—	%		0.7	%
Dental
Consumable		$	337,489			$	356,654			(5.4	)%		(0.5	)%		—	%		(4.9	)%
Equipment and software			214,006				193,437			10.6			(0.5	)		—			11.1
Value-added services and other			77,428				72,124			7.4			(0.4	)		—			7.8
Total		$	628,923			$	622,215			1.1	%		(0.5	)%		—	%		1.6	%
Animal Health
Consumable		$	963,767			$	988,158			(2.5	)%		(3.1	)%		—	%		0.6	%
Equipment and software			29,890				30,376			(1.6	)		—			—			(1.6	)
Value-added services and other			9,339				8,933			4.5			(15.0	)		—			19.5
Total		$	1,002,996			$	1,027,467			(2.4	)%		(3.1	)%		—	%		0.7	%
Corporate
Value-added services and other		$	(5,715	)		$	(521	)		n/m			—	%		—	%		n/m
Total		$	(5,715	)		$	(521	)		n/m			—	%		—	%		n/m

PATTERSON COMPANIES, INC. SALES SUMMARY (Dollars in thousands) (Unaudited)
		October 29, 2022				October 30, 2021			Total Sales Growth			Foreign Exchange Impact			53rd Week			Internal Sales Growth
Six Months Ended
Consolidated net sales
Consumable		$	2,563,025			$	2,686,486		(4.6	)%		(2.2	)%		(3.6	)%		1.2	%
Equipment and software			417,831				407,265		2.6			(0.4	)		(3.2	)		6.2
Value-added services and other			168,613				170,286		(1.0	)		(1.7	)		(2.9	)		3.6
Total		$	3,149,469			$	3,264,037		(3.5	)%		(1.9	)%		(3.5	)%		1.9	%
Dental
Consumable		$	675,329			$	733,230		(7.9	)%		(0.5	)%		(3.6	)%		(3.8	)%
Equipment and software			360,516				350,403		2.9			(0.5	)		(3.1	)		6.5
Value-added services and other			150,995				145,449		3.8			(0.4	)		(2.9	)		7.1
Total		$	1,186,840			$	1,229,082		(3.4	)%		(0.5	)%		(3.4	)%		0.5	%
Animal Health
Consumable		$	1,887,696			$	1,953,256		(3.4	)%		(2.8	)%		(3.6	)%		3.0	%
Equipment and software			57,315				56,862		0.8			—			(3.6	)		4.4
Value-added services and other			18,355				20,139		(8.9	)		(11.6	)		(3.9	)		6.6
Total		$	1,963,366			$	2,030,257		(3.3	)%		(2.8	)%		(3.6	)%		3.1	%
Corporate
Value-added services and other		$	(737	)		$	4,698		n/m			—	%		—	%		n/m
Total		$	(737	)		$	4,698		n/m			—	%		—	%		n/m

PATTERSON COMPANIES, INC. OPERATING INCOME BY SEGMENT (In thousands) (Unaudited)
		Three Months Ended								Six Months Ended
		October 29, 2022				October 30, 2021				October 29, 2022				October 30, 2021
Operating income (loss)
Dental		$	60,950			$	55,570			$	97,845			$	54,484
Animal Health			28,316				26,135				50,175				49,940
Corporate			(29,171	)			(18,845	)			(53,081	)			(81,093	)
Total		$	60,095			$	62,860			$	94,939			$	23,331

PATTERSON COMPANIES, INC. RECONCILIATION OF GAAP TO NON-GAAP MEASURES (Dollars in thousands, except per share amounts) (Unaudited)
For the three months ended October 29, 2022		GAAP				Deal amortization			Integration and business restructuring expenses			Legal reserves			Inventory donation charges			Gains on investments			Non-GAAP
Operating income		$	60,095			$	9,327		$	—		$	—		$	—		$	—		$	69,422
Other income (expense), net			10,659				—			—			—			—			—			10,659
Income before taxes			70,754				9,327			—			—			—			—			80,081
Income tax expense			17,105				2,237			—			—			—			—			19,342
Net income			53,649				7,090			—			—			—			—			60,739
Net loss attributable to noncontrolling interests			(424	)			—			—			—			—			—			(424	)
Net income attributable to Patterson Companies, Inc.		$	54,073			$	7,090		$	—		$	—		$	—		$	—		$	61,163
Diluted earnings per share attributable to Patterson Companies, Inc.*		$	0.55			$	0.07		$	—		$	—		$	—		$	—		$	0.63
Operating income as a % of sales			3.7	%																		4.3	%
Effective tax rate			24.2	%																		24.2	%
For the three months ended October 30, 2021		GAAP				Deal amortization			Integration and business restructuring expenses			Legal reserves			Inventory donation charges			Gains on investments			Non-GAAP
Operating income		$	62,860			$	9,614		$	1,863		$	—		$	—		$	—		$	74,337
Other income (expense), net			1,283				—			—			—			—			—			1,283
Income before taxes			64,143				9,614			1,863			—			—			—			75,620
Income tax expense			16,205				2,269			466			—			—			—			18,940
Net income			47,938				7,345			1,397			—			—			—			56,680
Net loss attributable to noncontrolling interests			(392	)			—			—			—			—			—			(392	)
Net income attributable to Patterson Companies, Inc.		$	48,330			$	7,345		$	1,397		$	—		$	—		$	—		$	57,072
Diluted earnings per share attributable to Patterson Companies, Inc.*		$	0.49			$	0.07		$	0.01		$	—		$	—		$	—		$	0.58
Operating income as a % of sales			3.8	%																		4.5	%
Effective tax rate			25.3	%																		25.0	%
* May not sum due to rounding

PATTERSON COMPANIES, INC. RECONCILIATION OF GAAP TO NON-GAAP MEASURES (Dollars in thousands, except per share amounts) (Unaudited)
For the six months ended October 29, 2022		GAAP				Deal amortization			Integration and business restructuring expenses			Legal reserves			Inventory donation charges			Gains on investments				Non-GAAP
Operating income		$	94,939			$	18,678		$	—		$	—		$	—		$	—			$	113,617
Other income (expense), net			6,876				—			—			—			—			—				6,876
Income before taxes			101,815				18,678			—			—			—			—				120,493
Income tax expense			23,906				4,474			—			—			—			—				28,380
Net income			77,909				14,204			—			—			—			—				92,113
Net loss attributable to noncontrolling interests			(754	)			—			—			—			—			—				(754	)
Net income attributable to Patterson Companies, Inc.		$	78,663			$	14,204		$	—		$	—		$	—		$	—			$	92,867
Diluted earnings per share attributable to Patterson Companies, Inc.*		$	0.81			$	0.15		$	—		$	—		$	—		$	—			$	0.95
Operating income as a % of sales			3.0	%																			3.6	%
Effective tax rate			23.5	%																			23.6	%
For the six months ended October 30, 2021		GAAP				Deal amortization			Integration and business restructuring expenses			Legal reserves			Inventory donation charges			Gains on investments				Non-GAAP
Operating income		$	23,331			$	19,155		$	4,245		$	36,000		$	49,194		$	—			$	131,925
Other income (expense), net			85,338				—			—			—			—			(87,827	)			(2,489	)
Income before taxes			108,669				19,155			4,245			36,000			49,194			(87,827	)			129,436
Income tax expense			26,929				4,506			1,061			8,460			12,308			(22,396	)			30,868
Net income			81,740				14,649			3,184			27,540			36,886			(65,431	)			98,568
Net loss attributable to noncontrolling interests			(586	)			—			—			—			—			—				(586	)
Net income attributable to Patterson Companies, Inc.		$	82,326			$	14,649		$	3,184		$	27,540		$	36,886		$	(65,431	)		$	99,154
Diluted earnings per share attributable to Patterson Companies, Inc.*		$	0.84			$	0.15		$	0.03		$	0.28		$	0.37		$	(0.67	)		$	1.01
Operating income as a % of sales			0.7	%																			4.0	%
Effective tax rate			24.8	%																			23.8	%
* May not sum due to rounding

PATTERSON COMPANIES, INC. FREE CASH FLOW (In thousands) (Unaudited)
		Six Months Ended
		October 29, 2022				October 30, 2021
Net cash used in operating activities		$	(520,161	)		$	(539,014	)
Additions to property and equipment			(26,779	)			(15,503	)
Collection of deferred purchase price receivables			489,639				585,647
Free cash flow		$	(57,301	)		$	31,130

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221201005343/en/

INVESTOR CONTACT: John M. Wright, Investor Relations

TEL: 651.686.1364

EMAIL: investor.relations@pattersoncompanies.com



MEDIA CONTACT: Patterson Corporate Communications

TEL: 651.905.3349

EMAIL: corporate.communications@pattersoncompanies.com



WEB: pattersoncompanies.com

Source: Patterson Companies, Inc.

FAQ

What are Patterson Companies' Q2 fiscal 2023 earnings results?

Patterson Companies reported Q2 earnings of $0.55 per diluted share, an increase from $0.49 year-over-year.

How did Patterson perform in terms of sales in Q2 fiscal 2023?

Patterson reported net sales of $1.63 billion in Q2 fiscal 2023, down 1.4% from the same period last year.

What is the fiscal 2023 earnings guidance for PDCO?

Patterson Companies reaffirmed its fiscal 2023 GAAP earnings guidance of $1.96 to $2.06 per diluted share.

What contributed to the increase in adjusted earnings for Patterson Companies?

The increase in adjusted earnings was primarily due to operating margin expansion in both the Dental and Animal Health segments.